NCT01628471View on ClinicalTrials.gov

MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

decitabine in combination with genistein

decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine

Trial Locations (1)

H2L 4M1

Hôpital Notre Dame du CHUM, Montreal

All Listed Sponsors
collaborator

DSM Nutritional Products, Inc.

INDUSTRY

collaborator

MDEIE Ministry, Québec Government

UNKNOWN

collaborator

INRS-Institut Armand Frappier , Université du Québec

UNKNOWN

lead

Uman Pharma

INDUSTRY

NCT01628471 - MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter